BMS-202

Catalog No.S7912 Batch:S791201

Print

Technical Data

Formula

C25H29N3O3
Molecular Weight 419.52 CAS No. 1675203-84-5
Solubility (25°C)* In vitro DMSO 83 mg/mL (197.84 mM)
Ethanol 83 mg/mL (197.84 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
Targets
PD-1/PD-L1 interaction [2]
(Cell-free assay)
0.018 μM
In vitro

BMS-202 inhibits PD-1/PD-L1 binding in SCC-3 and Jurkat cells with IC50 of 15 μM and 10 μM, respectively.
In vivo

BMS-202 treatment shows a clear antitumor effect compared with the controls, in humanized MHC- dKO NOG mice.

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    SCC-3 and Jurkat cells

  • Concentrations

    IC50 of 15 μM and 10 μM

  • Incubation Time

    4 days

  • Method

    Cells were treated with various concentrations of drug for 4 days.
Animal Study:

[3]
  • Animal Models

    NOG-dKO mice

  • Dosages

    20 mg/kg

  • Administration

    i.p.

References

  • https://patents.google.com/patent/WO2015034820A1
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058683/
  • https://pubmed.ncbi.nlm.nih.gov/31839668/

Selleck's BMS-202 Has Been Cited by 29 Publications

Intracellular Localization of PD-L1 in Rab10-positive Open Tubular Endosome System of Cancer Cells [ Acta Histochemica et Cytochemica, February 27, 2026, 49-57] PubMed: 41810323
Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib [ Anticancer Research, February 15, 2024, 503-510] PubMed: 38307554
Molecular Targeted Agent and Immune Checkpoint Inhibitor Co-Loaded Thermosensitive Hydrogel for Synergistic Therapy of Rectal Cancer [ Frontiers in Pharmacology, April 16, 2021, 671611] PubMed: 33935796
Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer [ Front Immunol, 2025, 16:1529710] PubMed: 40109332
Itraconazole inhibits the Wnt/β-catenin signaling pathway to induce tumor-associated macrophages polarization to enhance the efficacy of immunotherapy in endometrial cancer [ Front Oncol, 2025, 15:1590095] PubMed: 40697374
Metabolic profiling of glioblastoma and identification of G0S2 as a metabolic target [ Front Oncol, 2025, 15:1572040] PubMed: 40519301
Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model [ Sci Rep, 2025, 15(1):26918] PubMed: 40707559
In Vivo Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models [ In Vivo, 2025, 39(1):80-95] PubMed: 39740910
Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade [ Phytomedicine, 2024, 125:155370] PubMed: 38266440
Development and In Vivo Evaluation of Small-Molecule Ligands for Positron Emission Tomography of Immune Checkpoint Modulation Targeting Programmed Cell Death 1 Ligand 1 [ J Med Chem, 2024, 67(5):4036-4062] PubMed: 38442487

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.